- Allscripts Healthcare Solutions ( NASDAQ: MDRX ) reaffirmed its 2022 financial guidance, including $110M-$120M of free cash flow.
- Also, the company said its Veradigm data insights segment would have 6%-7% revenue growth and 10%-15% year-over-year adjusted EBITDA growth.
- During an investor day presentation earlier Wednesday, Allscripts ( MDRX ) management used the opportunity to showcase its competitive advantages and benefits for providers and payers.
- Despite the presentation, shares are down ~2% in Wednesday afternoon trading.
- Seeking Alpha's Quant Rating views Allscripts ( MDRX ) with high marks for profitability and momentum .
For further details see:
Allscripts Healthcare reaffirms 2022 financial guidance; shares fall 2%